A Phase I Maximum Tolerated Dose Study of CI-1012 in Late-Stage HIV+ Patients

Summary

To determine the maximum tolerated dose of CI-1012 in late-stage HIV-1-infected patients. To determine the antiretroviral activity of CI-1012 when added to combination therapy. To assess the multiple-dose pharmacokinetic characteristics of CT-1012 when added to combination therapy. To assess the effect of CI-1012 on the pharmacokinetics of other antiretroviral agents.

Timeline

Start

—

Primary completion

—

Completion

—

Drugs

Indications